vs
Side-by-side financial comparison of Xiao-I Corp (AIXI) and Gossamer Bio, Inc. (GOSS). Click either name above to swap in a different company.
Gossamer Bio, Inc. is the larger business by last-quarter revenue ($13.8M vs $11.5M, roughly 1.2× Xiao-I Corp). Xiao-I Corp runs the higher net margin — -263.9% vs -342.3%, a 78.5% gap on every dollar of revenue.
Xiao-i is a Chinese cognitive artificial intelligence enterprise founded in 2001.
Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics for patients with serious immunology, inflammation and oncology conditions. It advances a pipeline of proprietary product candidates across multiple clinical phases, primarily serving healthcare markets in North America and other global regions.
AIXI vs GOSS — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $11.5M | $13.8M |
| Net Profit | $-30.4M | $-47.2M |
| Gross Margin | 58.1% | — |
| Operating Margin | -254.9% | -333.6% |
| Net Margin | -263.9% | -342.3% |
| Revenue YoY | — | 47.1% |
| Net Profit YoY | — | -43.0% |
| EPS (diluted) | — | $-0.21 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $13.8M | ||
| Q3 25 | — | $13.3M | ||
| Q2 25 | $11.5M | — | ||
| Q2 24 | $33.0M | $95.8M | ||
| Q1 24 | — | $0 | ||
| Q3 23 | — | $0 | ||
| Q2 23 | $26.5M | $0 |
| Q4 25 | — | $-47.2M | ||
| Q3 25 | — | $-48.2M | ||
| Q2 25 | $-30.4M | — | ||
| Q2 24 | $-15.5M | $49.2M | ||
| Q1 24 | — | $-41.9M | ||
| Q3 23 | — | $-40.0M | ||
| Q2 23 | $-18.8M | $-42.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 58.1% | — | ||
| Q2 24 | 64.5% | — | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | 77.3% | — |
| Q4 25 | — | -333.6% | ||
| Q3 25 | — | -369.4% | ||
| Q2 25 | -254.9% | — | ||
| Q2 24 | -45.0% | 54.3% | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | -51.5% | — |
| Q4 25 | — | -342.3% | ||
| Q3 25 | — | -362.7% | ||
| Q2 25 | -263.9% | — | ||
| Q2 24 | -47.2% | 51.4% | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | -70.9% | — |
| Q4 25 | — | $-0.21 | ||
| Q3 25 | — | $-0.21 | ||
| Q2 25 | — | — | ||
| Q2 24 | $-0.64 | $0.22 | ||
| Q1 24 | — | $-0.19 | ||
| Q3 23 | — | $-0.21 | ||
| Q2 23 | $-0.80 | $-0.45 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $5.0M | $136.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $-122.8M |
| Total Assets | $82.4M | $172.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $136.9M | ||
| Q3 25 | — | $180.2M | ||
| Q2 25 | $5.0M | — | ||
| Q2 24 | $1.8M | $354.5M | ||
| Q1 24 | — | $244.4M | ||
| Q3 23 | — | $328.9M | ||
| Q2 23 | $4.7M | $162.1M |
| Q4 25 | — | $-122.8M | ||
| Q3 25 | — | $-82.3M | ||
| Q2 25 | — | — | ||
| Q2 24 | — | $81.5M | ||
| Q1 24 | — | $26.7M | ||
| Q3 23 | — | $104.6M | ||
| Q2 23 | $525.1K | $-62.8M |
| Q4 25 | — | $172.2M | ||
| Q3 25 | — | $208.8M | ||
| Q2 25 | $82.4M | — | ||
| Q2 24 | $87.6M | $373.4M | ||
| Q1 24 | — | $259.4M | ||
| Q3 23 | — | $347.9M | ||
| Q2 23 | $51.3M | $181.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-2.3M | $-48.3M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-48.3M | ||
| Q3 25 | — | $-36.2M | ||
| Q2 25 | $-2.3M | — | ||
| Q2 24 | — | $116.3M | ||
| Q1 24 | — | $-52.3M | ||
| Q3 23 | — | $-34.5M | ||
| Q2 23 | — | $-38.3M |
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | — | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q2 24 | — | 2.36× | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
